Navamedic adjusted EBITDA margin drops 1.9 percentage points to 5.5% in Q2 FY26; revenue rises 3.3% to NOK 278.3 million in H1 FY26

Reuters2026/08/14 05:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Navamedic posted H1 2026 revenue of NOK 278.3 million, up 3.3% year on year, with gross margin of 38.9%.
Adjusted EBITDA margin rose 1.7 percentage points to 10.2% in H1 2026.
Q2 2026 EBITDA margin fell 1.9 percentage points to 5.5% due to CEO-change costs and inventory write-offs.
Q2 prescription drugs revenue rose to NOK 74.3 million, including NOK 14.5 million from the addiction portfolio acquired in July 2025.
Outlook: 2026 revenue seen around 2025 levels, with improved gross margins and EBITDA on product mix and operational efficiencies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Navamedic ASA published the original content used to generate this news brief via Cision (Ref. ID: 20260814:BIT:7708:0) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Navamedic adjusted EBITDA margin drops 1.9 percentage points to 5.5% in Q2 FY26; revenue rises 3.3% to NOK 278.3 million in H1 FY26

You may also like

Crypto prices